Thoracic Ablation: Primary Lung Cancer, Metastases, Chest Wall Disease

  • Shuvro Roy-Choudhury
Part of the Techniques in Interventional Radiology book series (TECHRAD)


Radiofrequency ablation (RFA) of small volume primary and metastatic lung tumor is being increasingly performed in a curative setting as well as to control symptoms in a palliative setting. When used judiciously in a multidisciplinary setting it can deliver results comparable to other treatment modalities. In this chapter we will review the technical and clinical aspects of lung RFA to deliver a safe and effective service. Multiplanar review of the preprocedure CT is essential to plan access and treatment volumes. CT guidance is used for needle positioning to create an appropriate ablation geometry. Overtreatment is the key to success – a ground glass margin of 5 mm or greater all around the tumor with complete tumor necrosis and good local control reduces risk of recurrence. Rigorous imaging follow-up is critical – CT is usually performed, although PET at 3–6 months could be better. Local nodular recurrence, if detected early, can be successfully retreated. Complications like pneumothorax, haemorrhage, pleural reaction and post embolisation syndrome do occur, more than RFA of other sites. Although less used, microwave ablation, cryoablation, or sequential radiofrequency ablation may offer several advantages over standard unipolar radiofrequency ablation in the lungs.


Ground Glass Opacity Microwave Ablation Pleural Surface Good Local Control Primary Lung Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. Anderson EM, Lees WR, Gillams AR. Early indicators of treatment success after percutaneous radiofrequency of pulmonary tumors. Cardiovasc Intervent Radiol. 2009;32(3):478–83.PubMedCrossRefGoogle Scholar
  2. Bojarski JD, Dupuy DE, Mayo-Smith WW. CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: results in 32 tumors. AJR Am J Roentgenol. 2005;185(2):466–71.PubMedGoogle Scholar
  3. Chan VO, McDermott S, Malone DE, Dodd JD. Percutaneous radiofrequency ablation of lung tumors: evaluation of the literature using evidence-based techniques. J Thorac Imaging. 2011;26(1):18–26.PubMedCrossRefGoogle Scholar
  4. de Baère T. Lung tumor radiofrequency ablation: where do we stand? Cardiovasc Intervent Radiol. 2011;34(2):241–51.PubMedCrossRefGoogle Scholar
  5. de Baère T, Palussière J, Aupérin A, Hakime A, Abdel-Rehim M, Kind M, Dromain C, Ravaud A, Tebboune N, Boige V, Malka D, Lafont C, Ducreux M. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240(2):587–96.PubMedCrossRefGoogle Scholar
  6. Deandreis D, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, Deschamps F, Rao P, Schlumberger M, de Baère T. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology. 2011;258(1):270–6.PubMedCrossRefGoogle Scholar
  7. Fernando HC, Schuchert M, Landreneau R, Daly BT. Approaching the high-risk patient: sublobar resection, stereotactic body radiation therapy, or radiofrequency ablation. Ann Thorac Surg. 2010;89(6):S2123–7.PubMedCrossRefGoogle Scholar
  8. Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J, Nakatsuka A. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol. 2011;197(4):W576–80.PubMedCrossRefGoogle Scholar
  9. Lee H, Jin GY, Han YM, Chung GH, Lee YC, Kwon KS, Lynch D. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol. 2012;35(2):343–50.PubMedCrossRefGoogle Scholar
  10. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9(7):621–8.PubMedCrossRefGoogle Scholar
  11. Sonntag PD, Hinshaw JL, Lubner MG, Brace CL, Lee FT Jr. Thermal ablation of lung tumors. Surg Oncol Clin N Am. 2011;20(2):369–87, ix.Google Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Diagnostic and Interventional RadiologyFortis HospitalsKolkataIndia
  2. 2.Consultant Radiologist, Heart of England NHS Foundation TrustBirminghamUK

Personalised recommendations